The PRL2 phosphatase up-regulates miR-21 through activation of the JAK2/STAT3 pathway to down-regulate the PTEN tumor suppressor
Biochemical Journal · 2025
DOI: 10.1042/bcj20240626 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Journal, 2025. Verfasst von Qinglin Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Borch Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, 720 Clinic Drive, West Lafayette, IN 47907, U.S.A. Hauptthemen laut MEDLINE: MicroRNAs, PTEN Phosphohydrolase, Janus Kinase 2, STAT3 Transcription Factor. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIA NIH HHS, HHS | National Institutes of Health.
Abstract (Originalsprache)
The phosphatases of regenerating liver (PRLs) are members of the protein tyrosine phosphatase (PTP) superfamily that play pro-oncogenic roles in cell proliferation, migration, and survival. We previously demonstrated that PRLs can post-translationally down-regulate PTEN, a tumor suppressor frequently inactivated in human cancers, by dephosphorylating PTEN at Tyr336, which promotes the NEDD4-mediated PTEN ubiquitination and proteasomal degradation. Here, we report that PRLs can also reduce PTEN expression by up-regulating microRNA-21 (miR-21), which is one of the most frequently overexpressed miRNAs in solid tumors. We observe a broad correlation between PRL and miR-21 levels in multiple human cancers. Mechanistically, PRL2, the most abundant and ubiquitously expressed PRL family member, promotes the JAK2/STAT3 pathway-mediated miR-21 expression by directly dephosphorylating JAK2 at Tyr570. Finally, we confirm that the PRL2-mediated miR-21 expression contributes to its oncogenic potential in breast cancer cells. Our study defines a new functional role of PRL2 in PTEN regulation through a miR-21-dependent post-transcriptional mechanism, in addition to our previously reported NEDD4-dependent post-translational PTEN regulation. Together, these studies further establish the PRLs as negative regulators of PTEN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Borch Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, 720 Clinic Drive, West Lafayette, IN 47907, U.S.A.
- Current address: Thermo Fisher Scientific, 5781 Van Allen Way, Carlsbad, CA 92008, USA.
- Department of Biochemistry, Purdue University, 720 Clinic Drive, West Lafayette, IN 47907, U.S.A.
- Division of Haematology and Immunology, Leeds Institute of Medical Research, University of Leeds, U.K.
- The James Tarpo Jr. and Margaret Tarpo Department of Chemistry, Purdue University, 720 Clinic Drive, West Lafayette, IN 47907, U.S.A.
- Purdue Institute for Cancer Research, Purdue University, 720 Clinic Drive, West Lafayette, IN, 47907, U.S.A.
ORCID-Profile: Qinglin Li, Yunpeng Bai, Frederick Nguele Meke, Emily L Lasse-Opsahl, Gina M Doody, W Andy Tao, Zhong-Yin Zhang
Förderung
- NCI NIH HHS
- NIA NIH HHS
- HHS | National Institutes of Health
Zitieren
APA
Li, Q., Bai, Y., Cavender, S. M., Miao, Y., Nguele Meke, F., Lasse-Opsahl, E. L., Zhu, P., Doody, G. M., Tao, W. A., & Zhang, Z. Y. (2025). The PRL2 phosphatase up-regulates miR-21 through activation of the JAK2/STAT3 pathway to down-regulate the PTEN tumor suppressor. Biochemical Journal. https://doi.org/10.1042/bcj20240626
Vancouver
Li Q, Bai Y, Cavender SM, Miao Y, Nguele Meke F, Lasse-Opsahl EL, et al. The PRL2 phosphatase up-regulates miR-21 through activation of the JAK2/STAT3 pathway to down-regulate the PTEN tumor suppressor. Biochemical Journal. 2025. doi:10.1042/bcj20240626
BibTeX
@article{Li2025,
author = {Li, Qinglin and Bai, Yunpeng and Cavender, Sarah M and Miao, Yiming and Nguele Meke, Frederick and Lasse-Opsahl, Emily L and Zhu, Peipei and Doody, Gina M and Tao, W Andy and Zhang, Zhong-Yin},
title = {The PRL2 phosphatase up-regulates miR-21 through activation of the JAK2/STAT3 pathway to down-regulate the PTEN tumor suppressor},
journal = {Biochemical Journal},
year = {2025},
doi = {10.1042/bcj20240626}
}
EUVIMED